HOME >> BIOLOGY >> NEWS
New evidence shows Rituximab halts damage to joints

New data, presented today at the Annual European Congress of Rheumatology show for the first time that a rheumatoid arthritis (RA) treatment, rituximab, is able to significantly inhibit the structural damage to joints caused by RA in patients who have long-standing disease and an inadequate response to one or more TNF (Tumour Necrosis Factor) inhibitors.

Prevention of joint structural damage in rheumatoid arthritis is a critical therapeutic outcome. Many patients respond well to the TNF inhibitors, a relatively new class of therapy which prevents TNF protein causing inflammation in rheumatoid arthritis, however approximately 30% - 40% of patients treated with this therapy experience either an inadequate response or are intolerant to such therapies. As such, the study was designed to investigate the effect at 1 year of rituximab (a new therapy targeting B-cells cells which create abnormal antibodies causing rheumatoid arthritis symptoms) plus methotrexate (an antimetabolite drug which inhibits the synthesis of DNA, RNA and protein, previously the gold standard in the treatment of rheumatoid arthritis) on joint structural damage, compared to methotrexate alone in rheumatoid patients with inadequate response to one or more TNF inhibitors.

The results reveal bone erosions in patients in the rituximab group were reduced by over half during the course of a year compared to patients receiving placebo (erosion scores of 0.59 and 1.32 respectively), as were the narrowing of joint spaces (scores of 0.41 and 0.99 respectively). In addition the proportion of patients with no change in erosion score was significantly higher in the rituximab group compared to placebo.

"These findings suggest that treatment with rituximab plus methotrexate is associated with significant inhibition of joint structural damage, an important finding in patients who do not currently respond to other treatments" explained Professor Edward Keystone, Rheumatology Department at the
'"/>

Contact: Mia Gannedahl
mia_gannedahl@uk.cohnwolfe.com
44-207-331-2325
European League Against Rheumatism
22-Jun-2006


Page: 1 2

Related biology news :

1. No evidence that widely prescribed statins protect against prostate cancer
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. CU researchers discover evidence of very recent human adaptation
4. Research finds evidence tropical cyclones have climate-control role
5. New evidence of human culture among primates
6. Study advances evidence for receptors role in alcohol pleasure and problems
7. Study provides first genetic evidence of long-lived African presence within Britain
8. More human-Neandertal mixing evidence uncovered
9. First evidence to show elephants, like humans, apes and dolphins, recognize themselves in mirror
10. New MUHC study adds more evidence to clear measles mumps rubella vaccine as a risk factor for autism
11. Possible evidence of cell division, differentiation found in oldest known embryo fossils

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... SAN MATEO, Calif. (PRWEB) , ... September 03, 2020 , ... ... that the Brilliant Smart Home System and its products are now available for purchase ... wholesale distributor of smart home, security, AV, and low-voltage products. In addition to being ...
(Date:9/3/2020)... , ... September 03, 2020 , ... ... data, today announced that an extensive third-party assessment of the company’s security practices ... when measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and ...
(Date:8/26/2020)... , ... August 24, 2020 , ... ... the treatment of chronic inflammatory and fibrotic diseases, today announced that Dr. Stacie ... of Drug Discovery. , Dr. Canan previously served as Executive Director of Global ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... , ... True Terpenes , the leading platform for terpene innovation, research ... research the medical potential of terpenes and the potential entourage effect , where ... is focused on expanding the recently launched line of effects-based terpenes - Terpology ...
(Date:8/12/2020)... ... August 12, 2020 , ... ... International), a global leader in FDA compliance consulting has been named on its ... companies. The list represents a unique look at the most successful companies within ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing ... announced that they have entered into a strategic partnership whereby Catalent will provide ...
Breaking Biology Technology:
Cached News: